Kilian Kelly - Cynata Therapeutics VP of Product Devel.
| CYYNF Stock | USD 0.19 0.00 0.00% |
VP
Kilian Kelly is VP of Product Devel. of Cynata Therapeutics Limited since 2019.
| Tenure | 5 years |
| Phone | 61 3 7067 6940 |
| Web | https://www.cynata.com |
Cynata Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1342) % which means that it has lost $0.1342 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2081) %, meaning that it generated substantial loss on money invested by shareholders. Cynata Therapeutics' management efficiency ratios could be used to measure how well Cynata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | VP Age | ||
| Raymond JD | Rigel Pharmaceuticals | 56 | |
| Scott Samuels | Geron | N/A | |
Management Performance
| Return On Equity | -0.21 | |||
| Return On Asset | -0.13 |
Cynata Therapeutics Leadership Team
Elected by the shareholders, the Cynata Therapeutics' board of directors comprises two types of representatives: Cynata Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cynata. The board's role is to monitor Cynata Therapeutics' management team and ensure that shareholders' interests are well served. Cynata Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cynata Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ross Macdonald, CEO, Managing Director, Executive Director | ||
| BBus FCIS, Company Sec | ||
| Kilian Kelly, VP of Product Devel. | ||
| Suzanne Lipe, Vice President - Alliance Management | ||
| Jolanta Airey, Chief Officer |
Cynata Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Cynata Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.70) % | |||
| Operating Margin | (0.78) % | |||
| Current Valuation | 12.47 M | |||
| Shares Outstanding | 143.28 M | |||
| Shares Owned By Insiders | 14.77 % | |||
| Shares Owned By Institutions | 24.80 % | |||
| Price To Book | 2.66 X | |||
| Price To Sales | 5.53 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Cynata Pink Sheet
Cynata Therapeutics financial ratios help investors to determine whether Cynata Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cynata with respect to the benefits of owning Cynata Therapeutics security.